Latest Organogenesis Inc. Stories
Recent analysis finds Medicare patients require fewer costly healthcare services when chronic diabetic foot wounds are treated with FDA-approved bioengineered cellular technologies CANTON,
Robust Analysis in Wound Care Uses Real-World Patient Data from Medicare Records CANTON, Mass., March 26, 2015 /PRNewswire/ -- Organogenesis Inc., a world leading regenerative medicine
CANTON, Mass., Feb. 4, 2015 /PRNewswire/ -- Organogenesis Inc., a world leading regenerative medicine company, announced today that MiMedx Group, Inc.
MARIETTA, Ga., Feb. 3, 2015 /PRNewswire/ -- MiMedx Group, Inc.
MARIETTA, Ga., Dec. 31, 2014 /PRNewswire/ -- MiMedx Group, Inc.
EpiFix® Treatment Results In Cost Saving In Excess Of 80% Compared To Apligraf® MARIETTA, Ga., Nov. 17, 2014 /PRNewswire/ -- MiMedx Group, Inc.
Access to Apligraf® is Improved for Veterans with Chronic Diabetic Foot Ulcers and Venous Leg Ulcers CANTON, Mass., Aug 4, 2014 /PRNewswire/ -- Organogenesis Inc.
MARIETTA, Ga., May 20, 2014 /PRNewswire/ -- MiMedx Group, Inc.
CANTON, Mass. and ORLANDO, Fla., April 22, 2014 /PRNewswire/ -- This week, Organogenesis Inc.
DUBLIN, February 4, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today releases historical income statements
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.